News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
The number of jobs held by women in the Philadelphia region's life sciences industry is growing at a faster rate than jobs held by men, according to a new report featured in the Philadelphia Business
The New York Post recently published an article discussing future applications of mRNA, including vaccinations against tuberculosis, malaria, high cholesterol, HIV, and more.
viTToria Biotherapeutics and Exyn Technologies, both startups co-founded by Penn faculty, won recent awards from the Philadelphia Alliance for Capital and Technologies.
Penn spinout Aevitas Therapeutics recently executed an asset purchase agreement with California-based biotechnology company 4D Molecular Therapeutics (4DMT).
Teva Pharmaceuticals and MedinCell recently received approval from the U.S. Food and Drug Administration (FDA) for UZEDY™ (risperidone).
Cabaletta Bio received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its drug CABA-201.
Penn spinout Verismo Therapeutics, which focuses on CAR T-cell therapy for solid tumors, has activated its STAR-101 Phase 1 clinical trial at Penn.
PCI’s Carter Caldwell, program director for the Penn Medicine Co-Investment Program, discussed his entrepreneurial career and shared advice for others looking to start businesses.
From CAR-T therapy to the mRNA covid-19 vaccine, the list of Penn-linked FDA approvals has been growing with each passing year.
On May 9th, PCI and the Philadelphia Alliance for Capital and Technologies (PACT) co-hosted the event "The Future of Wearable Technology" at the Pennovation Center as part of Philly Tech Week 2023